[Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
The paper discusses the results of combination chemotherapy of 652 patients using platinum derivatives. The treatment proved effective in patients with metastatic tumors (79.7%), ovarian cancer (71.2%) and breast carcinoma (71.2%). Longer survival was obtained in cases of complete regression of ovarian tumor and in effectively treated patients with breast cancer. Response was registered in 30.8% of cases of osteogenic sarcoma. Application of cisplatin in chemoradiation treatment for inoperable bladder cancer resulted in regression of tumor in 57.4%. Literature data on some newly developed platinum derivatives undergoing phase-I and -II clinical trials outside the USSR are discussed.